A pragmatic cluster RCT investigated the effectiveness of a pharmacist-led information technology-enabled (PINCER) intervention in reducing risk of medication errors, in England. General practices were randomised to computer-generated simple feedback audit reports on at-risk patients (control) or the PINCER intervention comprising feedback, educational outreach and dedicated support from a pharmacist (intervention). We compared the costs and benefits of the PINCER intervention versus control. METHODS: Costs (English NHS perspective), QALYs and net benefit were generated. Error rates and intervention costs (corrected for baseline) were combined with modelled projected harm and NHS cost, adjusted for proportion of each error. Probabilistic Markov models were constructed to quantify the economic impact of each medication error (NSAIDs, beta-blockers, ACE-inhibitors, diuretics, amiodarone, methotrexate, lithium). A five year time horizon was used. Costs and outcomes were discounted at 3.5%. RESULTS: Seventy-two practices (480942 patients) were randomised to either arm. Mean (SD) error rate reduction per practice (simple feedback vs PINCER) at 6 months was 12.90 (0.26) (p<0.001). In deterministic analysis, PINCER was dominant, generating 0.81 more QALYs and saving £2611 per practice. In probabilistic analysis, PINCER reached 57% probability of being cost-effective at £10000 ceiling willingness-to-pay (λ). The probability of PINCER being cost-effective had not increased beyond 57% at λ: £30000. The mean net benefit generated (λ: £30000) was £21 (SD £91). Practice size did not affect results. CONCLUSIONS: This is one of the first studies to estimate the economic impact of a safety-focused intervention in health care. In the basecase, PINCER is dominant. However, due to uncertainty around the clinical and economic consequences of some errors, PINCER could not be considered cost-effective under current decision rules. Correcting errors relating to certain drugs (NSAIDs and amiodarone) had more impact, such that PINCER may be cost-effective if the "right" errors are targeted. Future work will investigate including other errors.
OBJECTIVES: MTM services aim to optimize care and reduce costs for patients taking multiple chronic drugs (poly-pharmacy). This study examined the impact of face-to-face MTM services on drug expenditures, medical expenditures and total health care costs in. METHODS: MarketScan Commercial Claims and Encounters database was used to select: adults >18 years between January 1, 2007 and December 31, 2010, with face-to-face MTM (CPT codes 99605, 99606, 99607) , and poly-pharmacy (4 or more chronic medications in the 6-months prior to index date). The date of the first MTM encounter was the index date. A (100:1) age, gender-matched poly-pharmacy control group was formed; the index date was that of the matched MTM patient. Nearest-neighbor propensity score matching within a caliper (1:1) was run to form two exchangeable study groups (n=401) controlling for demographic, drug-related, clinical status-related and health services utilization-related covariates. A difference-in-differences (DID) model with gamma distribution and log link accounting for three times points (period 0: 6 months pre, periods 1 and 2: 6 and 12 months post index date respectively) was run for total costs and medical costs. RESULTS: Unadjusted DID estimates for period 1 were $3,327 and $6,496 for period 2. DID models showed that total health care costs were not significantly different between the two groups in period 1 but were 32% less (CI:7%-51%, p-value=0.017) in the MTM group in period 2. Period 2 cost reduction was driven by medical costs (34% reduction, CI:2%-44%, p-value=0.037); no significant differences in pharmacy costs were observed in both periods. CONCLUSIONS: Face-to-face MTM services reduced medical costs with no change in pharmacy costs for poly-pharmacy patients. Favorable economic outcomes were detected seven months after initial MTM exposure. MTM plays a crucial role in reducing overall health care costs for chronic poly-pharmacy patients.
PHS116 DRUG THERAPY MANAGEMENT REDUCES HOSPITAL UTILIZATION AND COSTS IN PATIENTS WITH DIABETES WHO ARE HIGH MEDICATION UTILIZERS
Brophy L 1 , Williams A 1 , Keleti D 2 , Michael KE 2 , Shepherd M 1 , Fox S 2 , Tan-Torres S 2 , Gelzer AD 2 , Tegenu M 1 , Berman E 2 1 PerformRx, Philadelphia, PA, USA, 2 AmeriHealth Mercy Family of Companies, Philadelphia, PA, USA OBJECTIVES: Patients whose diabetes is managed with polypharmacy are subject to increased risk of medication-related problems and non-adherence. The objective of this drug therapy management (DTM) program is to integrate pharmacy intervention with care management to improve health and reduce cost. METHODS: The DTM program is a collaboration between pharmacy benefits management (PerformRx) and health plan-based care management (Keystone Mercy Health Plan [KMHP] and AmeriHealth Mercy Health Plan [AMHP]) targeting members with diabetes who are high utilizers (≥15 medications). Pharmacists review member profiles to recommend evidence-based prescriber and/or member interventions (e.g., changes in therapy, medication reminders) Pharmacists work directly with prescribers to optimize drug therapy, while care management provides detailed member coaching to enhance medication adherence. The profiles of 954 DTM participants (690 KMHP; 264 AMHP)-with a mean seven-fold greater disease burden than the plan average (using DxCG prospective risk scoring)-were reviewed for services between November 1, 2010 to July, 1, 2011, followed by a 3-month claims run-out period, while profiles of 810 matched control participants (600 KMHP; 210 AMHP) were not reviewed. RESULTS: Inpatient (IP) admissions and emergency room (ER) utilization rates were lower in the DTM population; however, only the DTM group in KMHP demonstrated a statistically significant reduction in IP admissions compared to the control group (76.4%; p=0.0002). Additionally, although pharmacy-related costs were significantly increased across-the-board, the changes were not statistically significant between DTM and control groups; however, total costs (medical+pharmacy) were significantly reduced in the DTM group compared to the control group (47.8% for KMHP, p=0.0039; 50.7% for AMHP, p=0.0497). The overall acceptance rates for diabetes-specific DTM interventions for KMHP and AMHP members were 33% and 26%, respectively. CONCLUSIONS: DTM Participants demonstrated a significant total cost savings in both health plans, and modest-to-significant reductions in ER visits and IP admission compared to non-participants.
PHS117 THE RELATIONSHIP BETWEEN NURSE STAFFING AND PATIENT SATISFACTION IN EMERGENCY DEPARTMENTS
Daniel I Health Quality Ontario, Toronto, ON, Canada OBJECTIVES: Patient satisfaction is a key outcome measure being examined by researchers exploring the relationships between patient outcomes and hospital structure and care processes. Only a few non-generalizable studies, however, have explored the relationship of nurse staffing and patient satisfaction with nursing care in emergency departments of hospitals. METHODS: A mulit-level mixed model was developed using more than 182,000 patient satisfaction surveys collected over a five-year period from 153 emergency departments (EDs) in 107 hospitals in a range of Canadian ED settings including urban and rural, community and academic, and small and large health care institutions with varying sizes and case mix. Using an established conceptual framework for investigating the relationship between nurse staffing and patient outcomes, nineteen nurse staffing variables were initially investigated. Ultimately, however, only five staffing variables were used in the multi-level regression analyzes. These five variables included registered nurse (RN) proportion, RN agency proportion, percent full-time nurse worked hours, RN worked hours per patient length of stay and registered practical nurse (RPN) worked hours per length of stay. Emergency department case mix index, patient age and gender, hospital peer group, size, wait times, cleanliness of the emergency department, physician courtesy, and year of measurement were controlled to account for their effect on the relationship between nursing staffing and patient satisfaction in the ED. RESULTS: The study revealed a subset of six patient satisfaction variables representing the overall variation in patient satisfaction with nursing care in the ED. CONCLUSIONS: Although RN proportion and RPN worked hours per length of stay were found to have a statistical association with patient satisfaction in the ED, the association was weak and not administratively actionable. Interpersonal and environmental factors such as physician and nurse courtesy, ED cleanliness and timeliness, however, were areas where hospital administrators could improve patient satisfaction in EDs. 
PHS118 ATTITUDES TOWARDS THE ROLE OF COMMUNITY PHARMACISTS IN IRAQ

OBJECTIVES:
To assess public use of community pharmacies; evaluate attitudes towards the role of community pharmacist; and determine the required pharmacists' characteristics and future services. METHODS: It was a crosssectional study using stratified sampling technique among pharmacy-attendees in Baghdad from January to March 2012. Data gathered by using a validated selfadministered questionnaire. Mann-Whitney and Kruskal-Wallis tests were performed to find the statistical differences among the study variables. Further analysis by Chi-square test and logistic regression detected the predictors of public's attitudes. RESULTS: More than two thirds of respondents (70.0%) visited the community pharmacies once or more per month. Slightly, more than half of respondents (55.4%) rated community pharmacist as the first person to contact in case of any drug-related problem. However, poor attitudes towards the pharmacist's role were recognized among the majority of respondents (79.8%). Respondent characteristics have led to the significant differences in public attitudes. In the multivariate logistic analysis, gender and age were the influential predictors for the model. CONCLUSIONS: The use of community pharmacy in Iraq was characterized mainly by the frequent visits to purchase medicines. The selection of pharmacy depended on its location. Public has V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) A 1 -A 2 9 8 A207 poorly appreciated the professional performance of pharmacists. Therefore, raising the awareness about the important role of pharmacist in providing public health is warranted.
PHS119
PROFILE OF PATIENTS USING IMMUNOBIOLOGICAL IN A HEALTH PLAN OPERATOR, FORTALEZA, BRAZIL: ECONOMIC AND PHARMATHERAPEUTICS INDICATORS
Reis H 1 , Magalhães DDP 2 , Sartori DP 2 , Vieira JB 2 , Alcantara ACDC 2 , Filho AEAM 2 , Barsi UD 2 , Alencar JLL 2 , Ferreira J 3 , Fonseca DB 2 1 UNIMED, Fortaleza, Brazil, 2 Unimed Fortaleza, Fortaleza, Brazil, 3 UFC, Fortaleza, Brazil OBJECTIVES: To profile the use of an operator in immunobiological supplemental health Fortaleza -Brazil, to identify the most prescribed therapeutic regimens and costs. METHODS: Cross-sectional study in two hospitals accredited service provider, from March to November/2012. Data were recorded by medical expertise in computerized management system (Sabius ® ) performed after the medical consultation. Later, these were entered in Microsoft Excell 2007 and analyzed by pharmacists auditors. The cost was calculated from the value contained in Brasíndice Unit 765, using the Consumer Price Max. The doses used for rheumatoid arthritis Etanercept 50 mg, 40 mg Adalimumab, abatacept 750 mg, 300 mg infliximab, 560 mg Tocilizimabe, Rituximab 1g and Golimumab 50 mg based on a 70 kg adult. RESULTS: We analyzed 64 patients with a mean weight 67 kg, of which 70.31% (n = 45) were women aged 30-59 years whose most frequent indications were rheumatoid arthritis (n = 33, 51.56%) and ankylosing spondylitis (n = 19; 29.69%). The most immunobiological commonly prescribed were Infliximab (n = 36; 56.25%), Tocilizimabe (n = 11, 17.19%), abatacept, and Rituximab (n = 8; 12, 50%) and golimumab (n = 1, 1.56%). It was observed that 67% (n = 43) patients were naïve immunobiological and 33% (n = 21) initiated with anti-TNF, whereas 61.9% (n = 13) moved into one another with immunobiological mechanism of action and 38.1% (n = 8) continued with an anti-TNF, changing only the drug. The average cost of treatment/dose first line was R$ 6,068.91 and the second line was R$ 9,590.06, resulting in an incremental cost/dose of R$ 3,521.16 (36.72%). CONCLUSIONS: Knowledge of costs and pharmacotherapeutic profile becomes important for planning strategies aimed at streamlining and optimization of these drugs on quality of care.
PHS120 MEDICAL RE-ADMISSIONS AT THE ROYAL LONDON HOSPITAL -PATIENT SPECIFIC AND DISEASE SPECIFIC FACTORS AT ONE WEEK AND ONE MONTH
Ma L, Wilkinson H, Saleh A, Raichura H, Wilson L, Emmanuel J Royal London Hospital NHS Trust, London, UK
OBJECTIVES: The Royal London Hospital is a teaching hospital in East London, UK. We hypothesised that medical patients with multiple co-morbidities and complex disease are likely to present with a new diagnosis when re-admitted within a month. Further, re-admission within a week is likely to be related to the initial diagnosis. METHODS: We conducted a retrospective audit of all nonelective adult acute medical admissions over a 6 week period during 2012. We collected information on patient demographics, ICD-10 diagnosis, length of hospital stay, along with readmissions within one week and one month. We reviewed the original and subsequent electronic discharge summaries. We highlight patient specific and disease specific factors. RESULTS: There were a total of 124 readmissions from the original audit (n=859). A large proportion (40%) of all readmissions were in the elderly (over the age of 70). There were 73 (59%) readmissions within 1 month, and 37 (30%) within a week. Fourteen patients (11%) were readmitted within a week, and again within a month. COPD (33%), PE (29%), sepsis (26%) and cellulitis (24%) had the highest re-admission rates. Our audit points to a 14.4% readmission rate in our cohort. We aim to address the precipitating factors in our new physician led ambulatory care clinic. We highlight the bed days saved through such a clinic. CONCLUSIONS: Contrary to our hypothesis readmissions within a month were related to the original diagnosis, interestingly this was less so when re-admitted within a week. Our audit has helped highlight the need for better community management plans prior to discharge. This has led to closer links with the Community Rehabilitation and Support Team (CReST) in order to reduce readmission rates.
PHS121 DO PATIENTS NEED TO BE ACCOMPANIED IN ICU WARDS?
Zhang Y 1 , Zhang HY 2 , Qiao Y 1 1 General Hospital of Shenyang Military Region, Shenyang, China, 2 Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China OBJECTIVES: For treatment needs, accompany is limited for ICU patients. A 30minute visit a day is allowed for their families. However, mental disturbance have been reported in ICUs. Actually, patients suffer from not only diseases but also loneliness in the units. The study was conducted to answer the question whether ICU patients need to be accompanied? METHODS: A questionnaire survey consisting of 3 questions about the attitude to accompanies in ICU was conducted in General Hospital of Shenyang Military Area in China. The 3 questions are: 1) Do you need an accompanier when treated in ICU? (Yes/No); 2) If you need, who will be the candidate? (A family member/A paid nursing staff/A relative or friend/Anyone available); 3) How long do you need to stay with your family members each day in ICU? (Half an hour/One hour/Half a day/All day). After repeatability test, the questionnaire was filled by patients randomly selected in ICU wards of cardiology and general medical wards from January 1, to August 31, 2011. Chi-square tests were used to compare the choices between patients from different wards, of different gender and age. RESULTS: Repeatabilities for the 3 questions were 0.742, 0.783, and 0.785. Totally, 142 patients were involved in, including 69 ICU patients and 73 general patients, 117 males and 25 females, 53 young & middle aged (≤60 )and 89 old ones (>60). Fiftyseven percent of the patients needed accompaniers in ICU, 86.6% of the patients chose family members as the candidates, 74.6% of the patients needed all-day accompanies by family members. Percentages of patients needing half-day and all-day accompany by family members were higher in ICU and old patients than those in general and younger ones(P<0.05). CONCLUSIONS: Patients do need to be accompanied in ICU. An all-day accompany by family member is highly preferred. Wilkinson H, Ma L, Saleh A, Raichura H, Wilson L, Emmanuel J Royal London Hospital NHS Trust, London, UK OBJECTIVES: Many NHS hospitals have developed an Acute Medicine Unit to streamline all non-elective medical admissions. The cost of providing this secondary care service is funded by the local primary care team, who in turn receive funding from central government. However, teaching hospitals in the capitol would also care for a considerable number of international and national patients. We sought to examine if health care costs were reimbursed for these patients. METHODS: We undertook a retrospective audit of all admissions over a 6 week period at a central London teaching hospital. We collected patient demographics, ICD-10 diagnosis and length of stay. We identified all "out of area" patients and calculated costs incurred based on bed days, diagnosis and readmission within a month. The ICD-10 codes were converted to cost (HRG) codes through the finance office. RESULTS: A total of 864 admissions and 124 readmissions were analysed. In all 28% (n=242) of admissions were "out of area". This cohort accounted for 25% of bed occupancy, and cost the hospital £390,300. Further, 1% (n=8) of patients were of no fixed abode (homeless) and cost £7,200 in bed occupancy. The international patients account for 1% (n=6) and cost £4,500 in bed occupancy. The top 3 presenting complaints with disease management costs were; Sickle cell anaemia (n=27-£34,899) chest pain (n=24-£16,757) and lower respiratory tract infection (n=19-£69,288). We went on to compare the income generated from these admissions on an individual basis. Initial analysis point to a deficit in income generated. This has significant implications for the financial viability of secondary/tertiary care hospitals in the NHS. CONCLUSIONS: Our analysis point to a considerable financial burden from "out of area" patients to the capitol's hospitals. Reducing this financial burden does raise clinical and ethical challenges to the receiving hospital. 
PHS122 PIT FALLS OF THE NATIONAL HEALTH SERVICE (NHS) "INTERNAL MARKET" HEALTH CARE MODEL; DOES REIMBURSEMENT OF SECONDARY CARE MATCH COSTS INCURRED
PHS123 THE EFFECT OF COPAYMENTS FOR PRESCRIPTIONS ON ADHERENCE TO MEDICINES IN PUBLICLY INSURED POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS
OBJECTIVES:
To quantitatively estimate the effect of copayments for prescriptions on adherence to medicines in a publicly insured population. METHODS: Eight electronic databases and the grey literature were systematically searched by one reviewer for relevant articles, along with hand searches of references in review articles and the included studies. Studies were included if they involved a publicly insured population, an intervention which was the introduction of, or an increase in copayment and if the outcome was objectively measured adherence (or non-adherence) to medicines. Measures of adherence included Proportion of Days Covered and Medication Possession Ratio. Study exclusion, data extraction and quality appraisal were carried out by two independent reviewers. A random effects model was used to generate the metaanalysis in RevMan version 5.1. Statistical heterogeneity was assessed using the I 2 test; p=>0.1 indicated a lack of heterogeneity. RESULTS: Seven out of 41 studies met the inclusion criteria. Five studies contributed more than 1 result to the meta-analysis. The meta-analysis included 199, 996 people overall; 74, 236 people in the copayment group and 125,760 people in the non-copayment group. Average age was 71.75 years. In the copayment group, (verses the noncopayment group), the odds ratio for non-adherence was 1.11 (95% CI 1.09-1.14; P=<0.00001). An acceptable level of heterogeneity at I 2 =10%, (p=0.34) was observed. CONCLUSIONS: This meta-analysis showed an 11% increased odds of non-adherence to medicines in publicly insured populations involved in a system where copayments for medicines are necessary. Policy-makers should be wary of potential negative clinical outcomes resulting from lack of adherence. Unintended economic repercussions of copayments are possible.
PHS124 REIMBURSEMENT LANDSCAPE AND POLICY DEVELOPMENT FOR RARE DISEASES IN CHINA: A CASE STUDY OF HEMOPHILIA
